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To the Editor (In reply), 
 
We thank Wang et al.1 for their comments on our recent trial2. Firstly, we understand that some 
clinicians do not have access to droperidol. However, the midazolam-olanzapine combination 
has an efficacy and safety profile very similar to midazolam-droperidol3 and has potential as a 
suitable alternative.  
 
Of the 88 patients who received sedative medications prior to the first study medication, 19 were 
administered pre-hospital intramuscular midazolam according to the paramedic protocol. The 
median (IQR) dose and time prior to the first study medication was 10 (6-16) mg and 66 (38-
125) minutes, respectively. In the emergency department, a total of 105 doses of sedative 
medication were administered prior to the first study medication: median (IQR) time prior to the 
first study medication was 48 (23-89) minutes. The large majority were oral doses of diazepam 
(n=45) or olanzapine (n=36) with median (IQR) doses of 10 (10-10) mg for both medications. 
The remaining sedative medications included other benzodiazepines, antipsychotics and 
ketamine, via a range of administration routes.  
 
The use of any oral or parenteral benzodiazepine or neuroleptic (typically oral diazepam or 
olanzapine in our institutions) prior to enrolment was dichotomized into "yes" or "no" and added 
into the Cox regression model. This variable had no significant impact on the model. Given the 
small numbers and variability in medications, doses and timing, no further modelling of pre-
enrolment sedation was possible. 
 
We can confirm that the discrepancy between the Trial Registry information and our report was a 
clerical oversight. We designed the trial to have the most clinically relevant primary outcome i.e. 
‘proportion of patients adequately sedated at 10 minutes’. This primary outcome, and the sample 
size calculation based upon it, was recorded in the study protocol that was approved by our 
ethics committee before the study began. The term ‘time to sedation’ that we recorded in the 
Registry was too broad, as it could include both proportions sedated at various time points and 
actual times to sedation.  
 
The propensity of midazolam (alone or in combination) to cause respiratory events is well 
known.2,3 We agree that the risk/benefit of midazolam-droperidol use needs to be weighed. 
However, while the event rate is important, the consequences of these events also need to be 
considered. In this regard, the large majority of respiratory events are transient, easily managed 
and are of no clinical consequence. As Wang et al.1 suggest, there are confounding variables that 
impact upon respiratory events. In our study, patients intoxicated with alcohol had more 
respiratory events than those who did not (18.7% versus 12.1%, respectively). However, patients 
intoxicated with recreational drugs did not have more respiratory events (14.1% versus 15.5%, 
respectively). In a multi-centre study, we are currently investigating the impact of sedative 
medications, intoxication and other confounding variables on the risk of respiratory (and other) 
events.  
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